Chautauqua Capital Management, a division of Baird Asset Management, reported strong global equities performance in Q4 2025, with international markets outperforming U.S. equities due to a weaker dollar and improved trade conditions. Despite headwinds, the Baird Chautauqua International and Global Growth Funds focus on high-quality businesses with strong cash flows and balance sheets.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) was highlighted in the fourth-quarter 2025 investor letter for its biotechnology leadership and innovative medicines for serious diseases. The one-month return of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) was -0.30%, with shares trading approximately 12.42% above their 52-week high at around $762.65 per share on January 26, 2026.

Baird Chautauqua International and Global Growth Funds noted Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) reported strong 3Q25 results driven by Dupixent and Eylea HD, with third-party manufacturing issues likely to be resolved in 2026. The company anticipates important pipeline data readouts in 2026, positioning it for future growth and development.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is not among the 30 Most Popular Stocks Among Hedge Funds but was held by 78 hedge fund portfolios at the end of Q3 2025, up from 73 in the previous quarter. While acknowledging the potential of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), some AI stocks are believed to offer greater promise for higher returns in a shorter time frame.

Read more at Yahoo Finance: Regeneron (REGN) Posted Solid Quarterly Results, Eyes 2026 Pipeline Catalysts